Announcing a new publication for Acta Materia Medica journal. Monoamine oxidase (MAO) is a useful target in the treatment of neurodegenerative diseases and depressive disorders. Understanding the ...

The following is written by Sheldon S. Sones, RPh, FASCP, President, Sheldon S. Sones and Associates. Monoamine oxidase inhibitors (MAO inhibitors or MAOIs) are drugs which, by virtue of their ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, and safety of rasagiline are reviewed. Summary: Rasagiline is a novel, investigational propargylamine that irreversibly and selectively ...

Monoamine oxidase inhibitors (MAOIs) have a long and prosperous history as medications for major depressive disorder (MDD). But this type of antidepressant has mostly seen its day. Though MAOIs are ...

Parkinson’s disease is a condition that damages dopamine-producing brain cells, leading to tremors, stiffness, and difficulty with balance and coordination. Medications for Parkinson’s disease aim to ...

In the years after World War II, there were no effective medicines for schizophrenia, bipolar disorder, or major depression. There were not even names for such things. The word ‘antipsychotic’ was ...

Rheumatoid arthritis (RA) is an autoimmune disease that causes extensive inflammation of the joints, causing severe pain and discomfort in patients. But did you know that the disease is also commonly ...

Dopamine agonists and dopamine reuptake inhibitors (DRIs) appear to have equal efficacy for Parkinson's disease (PD) and motor fluctuations uncontrolled by levodopa. However, some DRIs are more ...